Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 2/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | CCR2 | P41597 | 2/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.44 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.43 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.43 |
| ▸ | NR4A3 | Q92570 | 1/20 | 0.43 |
| ▸ | CCR9 | P51686 | 2/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5882547 | 0.87 | LMNA (0.45) | LMNASMN1; SMN2NPSR1PPARGHPGD | |
| SCHEMBL5882169 | 0.86 | CCR2 (0.50) | SMN1; SMN2PPARGL3MBTL1CCR2NPC1 | |
| SCHEMBL5882472 | 0.86 | LMNA (0.46) | NR4A2LMNASMN1; SMN2NPSR1PPARG | |
| SCHEMBL6170044 | 0.81 | PPARG (0.64) | NR4A2LMNASMN1; SMN2NPSR1PPARG | |
| SCHEMBL11977114 | 0.79 | HDAC1 (0.59) | SMN1; SMN2PPARGHPGDL3MBTL1CCR2 | |
| SCHEMBL5881969 | 0.79 | PPARG (0.71) | LMNASMN1; SMN2PPARGHDAC1HDAC2 | |
| SCHEMBL6172342 | 0.79 | PPARG (0.54) | LMNASMN1; SMN2PPARGHPGDL3MBTL1 | |
| SCHEMBL11977113 | 0.79 | SMN1; SMN2 (0.46) | LMNASMN1; SMN2PPARGL3MBTL1NPC1 | |
| SCHEMBL6304929 | 0.78 | PPARG (0.52) | NR4A2LMNASMN1; SMN2NPSR1PPARG | |
| SCHEMBL6301156 | 0.78 | PPARG (0.52) | NR4A2LMNASMN1; SMN2NPSR1PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115647-B2 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. (US) | 2006-10-03 | — | — | US | disclosed |
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | OSI PHARMACEUTICALS, INC. | 2002-10-03 | — | — | US | disclosed |
| US-6410584-B1 | ANTICANCER AGENTS | CELL PATHWAYS, INC. | 2002-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143022-A1 | Method of inhibiting neoplastic cells with indole derivatives | IDO1, IDO2, INMT | NR4A2 3386/4885LMNA 2321/4885SMN1; SMN2 4694/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.